Patient characteristics
| Characteristic . | Total (N = 87) . | Axi-cel (n = 50; 57%) . | Liso-cel (n = 37; 43%) . | P value∗ . |
|---|---|---|---|---|
| Age, median (range), y | 66 (35-84) | 62 (35-82) | 73 (55-84) | <.001 |
| ≤65 | 43 (49) | 35 (70) | 8 (22) | <.001 |
| >65 | 44 (51) | 15 (30) | 29 (78) | |
| Female sex | 33 (38) | 20 (40) | 13 (35) | .66 |
| Pathologic diagnosis | ||||
| De novo DLBCL | 52 (60) | 27 (54) | 25 (68) | .44 |
| tFL | 18 (21) | 13 (26) | 5 (14) | |
| HGBL | 8 (9) | 4 (8) | 4 (11) | |
| tMZL | 3 (3) | 1 (2) | 2 (5) | |
| tCLL | 2 (2) | 2 (4) | - | |
| Other† | 4 (5) | 3 (6) | 1 (3) | |
| DHL | 12 (14) | 7 (14) | 5 (14) | >.99 |
| THL | 5 (6) | 3 (6) | 2 (5) | >.99 |
| Stage (at the time of diagnosis) | ||||
| I | 2 (2) | 1 (2) | 1 (3) | .92 |
| II | 5 (6) | 3 (6) | 2 (5) | |
| III | 14 (16) | 7 (14) | 7 (19) | |
| IV | 62 (71) | 37 (74) | 25 (68) | |
| ECOG PS (before apheresis) | ||||
| 0 | 16 (18) | 10 (20) | 6 (16) | .96 |
| 1 | 43 (49) | 24 (48) | 19 (51) | |
| 2 | 25 (29) | 14 (28) | 11 (30) | |
| 3 | 2 (2) | 1 (2) | 1 (3) | |
| IPI (before lymphodepletion) | ||||
| 0-2 | 15 (17) | 10 (20) | 5 (14) | .57 |
| 3-5 | 68 (78) | 37 (74) | 31 (84) | |
| Preinfusion lines of therapy, median (range) | 2 (2 - 3) | 2 (2 - 3) | 2 (2 - 3) | >.99 |
| 2 | 52 (60) | 30 (60) | 22 (59) | >.99 |
| 3 | 35 (40) | 20 (40) | 15 (41) | |
| Prior autologous transplant | 17 (20) | 12 (24) | 5 (14) | .28 |
| Prior allogeneic transplant | 2 (2) | 1 (2) | 1 (3) | >.99 |
| Bridging therapy | 53 (61) | 27 (54) | 26 (70) | .18 |
| Chemotherapy | 31 (36) | 13 (26) | 18 (49) | .041 |
| Radiation | 14 (16) | 7 (14) | 7 (19) | .57 |
| Steroid | 15 (17) | 9 (18) | 6 (16) | >.99 |
| Tumor bulk, median (range), cm | 3.7 (1.0-44.0) | 3.6 (1.0-44.0) | 4.5 (1.0-17.5) | .53 |
| ≤5 | 40 (46) | 25 (50) | 15 (41) | .59 |
| >5-10 | 15 (17) | 8 (16) | 7 (19) | |
| >10 | 7 (8) | 3 (6) | 4 (11) | |
| LDH before lymphodepletion, median (range), U/L | 226 (138-1603) | 218 (138-1603) | 235 (139-919) | .63 |
| SPD, median (range) | 20.0 (0-321) | 15.0 (0-272) | 23.1 (1.4-321) | .39 |
| SUVmax, median (range) | 16.2 (3.5-51.6) | 17.6 (3.5-40.9) | 13.7 (6.0-51.6) | .98 |
| Comorbidities | ||||
| BMI >30 | 23 (26) | 14 (28) | 9 (24) | .81 |
| Diabetes | 10 (11) | 3 (6) | 7 (19) | .09 |
| Statin use | 26 (30) | 12 (24) | 14 (38) | .24 |
| LVEF <50% | 5 (6) | 3 (6) | 2 (5) | >.99 |
| GFR <50 mL/min | 8 (9) | 3 (6) | 5 (14) | .28 |
| Characteristic . | Total (N = 87) . | Axi-cel (n = 50; 57%) . | Liso-cel (n = 37; 43%) . | P value∗ . |
|---|---|---|---|---|
| Age, median (range), y | 66 (35-84) | 62 (35-82) | 73 (55-84) | <.001 |
| ≤65 | 43 (49) | 35 (70) | 8 (22) | <.001 |
| >65 | 44 (51) | 15 (30) | 29 (78) | |
| Female sex | 33 (38) | 20 (40) | 13 (35) | .66 |
| Pathologic diagnosis | ||||
| De novo DLBCL | 52 (60) | 27 (54) | 25 (68) | .44 |
| tFL | 18 (21) | 13 (26) | 5 (14) | |
| HGBL | 8 (9) | 4 (8) | 4 (11) | |
| tMZL | 3 (3) | 1 (2) | 2 (5) | |
| tCLL | 2 (2) | 2 (4) | - | |
| Other† | 4 (5) | 3 (6) | 1 (3) | |
| DHL | 12 (14) | 7 (14) | 5 (14) | >.99 |
| THL | 5 (6) | 3 (6) | 2 (5) | >.99 |
| Stage (at the time of diagnosis) | ||||
| I | 2 (2) | 1 (2) | 1 (3) | .92 |
| II | 5 (6) | 3 (6) | 2 (5) | |
| III | 14 (16) | 7 (14) | 7 (19) | |
| IV | 62 (71) | 37 (74) | 25 (68) | |
| ECOG PS (before apheresis) | ||||
| 0 | 16 (18) | 10 (20) | 6 (16) | .96 |
| 1 | 43 (49) | 24 (48) | 19 (51) | |
| 2 | 25 (29) | 14 (28) | 11 (30) | |
| 3 | 2 (2) | 1 (2) | 1 (3) | |
| IPI (before lymphodepletion) | ||||
| 0-2 | 15 (17) | 10 (20) | 5 (14) | .57 |
| 3-5 | 68 (78) | 37 (74) | 31 (84) | |
| Preinfusion lines of therapy, median (range) | 2 (2 - 3) | 2 (2 - 3) | 2 (2 - 3) | >.99 |
| 2 | 52 (60) | 30 (60) | 22 (59) | >.99 |
| 3 | 35 (40) | 20 (40) | 15 (41) | |
| Prior autologous transplant | 17 (20) | 12 (24) | 5 (14) | .28 |
| Prior allogeneic transplant | 2 (2) | 1 (2) | 1 (3) | >.99 |
| Bridging therapy | 53 (61) | 27 (54) | 26 (70) | .18 |
| Chemotherapy | 31 (36) | 13 (26) | 18 (49) | .041 |
| Radiation | 14 (16) | 7 (14) | 7 (19) | .57 |
| Steroid | 15 (17) | 9 (18) | 6 (16) | >.99 |
| Tumor bulk, median (range), cm | 3.7 (1.0-44.0) | 3.6 (1.0-44.0) | 4.5 (1.0-17.5) | .53 |
| ≤5 | 40 (46) | 25 (50) | 15 (41) | .59 |
| >5-10 | 15 (17) | 8 (16) | 7 (19) | |
| >10 | 7 (8) | 3 (6) | 4 (11) | |
| LDH before lymphodepletion, median (range), U/L | 226 (138-1603) | 218 (138-1603) | 235 (139-919) | .63 |
| SPD, median (range) | 20.0 (0-321) | 15.0 (0-272) | 23.1 (1.4-321) | .39 |
| SUVmax, median (range) | 16.2 (3.5-51.6) | 17.6 (3.5-40.9) | 13.7 (6.0-51.6) | .98 |
| Comorbidities | ||||
| BMI >30 | 23 (26) | 14 (28) | 9 (24) | .81 |
| Diabetes | 10 (11) | 3 (6) | 7 (19) | .09 |
| Statin use | 26 (30) | 12 (24) | 14 (38) | .24 |
| LVEF <50% | 5 (6) | 3 (6) | 2 (5) | >.99 |
| GFR <50 mL/min | 8 (9) | 3 (6) | 5 (14) | .28 |
BMI, body mass index; DHL, double-hit lymphoma; DLBCL, diffuse LBCL; ECOG PS, Eastern Cooperative Oncology Group performance status; GFR, glomerular filtration rate; HGBL, high-grade B-cell lymphoma; IPI, International Prognostic Index; LVEF, left ventricular ejection fraction; SUVmax, maximum standardized uptake value; tCLL, transformed chronic lymphocytic leukemia; tFL, transformed follicular lymphoma; THL, triple-hit lymphoma; tMZL, transformed marginal zone lymphoma.
Continuous variables compared using Wilcoxon rank-sum test and categorical variables using Fisher exact test.
Other diagnoses include T-cell/histiocyte rich B-cell lymphoma (1), primary mediastinal B-cell lymphoma (1), transformed Waldenström macroglobulinemia (1), and Burkitt lymphoma (1).